Login
Amgen NASDAQ: AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience
| Name | Amgen |
| Ticker | AMGN |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
|
Price
52W Low/High |
250.86
216.38 / 260.95 |
| Momentum | Neutral |
| Market cap | 145 B |
| 1Y Total Return |
11.71%
Weak |
| 1Y Volatility |
25.72%
Low Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience
Details
| Ticker | AMGN |
| Name | Amgen |
| ISIN | US0311621009 |
| CUSIP | 031162100 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) |
|
Share as of 5/18/21
| Close Price | 250.86 |
| 52W Low/High | 216.38 / 260.95 |
| Market cap | 145 B |
| 1Y Total Return |
11.71%
Weak |
| 1Y Volatility |
25.72%
Low Risk |
| Beta | 0.77 |
| PE (trailing) |
20.77
Below Average |
| 12M Dividends | 6.56 |
| Last Dividend Date | 11/13/20 |
| Dividend Yield | 2.62% |
Fin. Strength
| Net Profit Margin | 28.2% |
| Cash from Op. / Cur. Liabilities | 0.81 |
| Diluted Earnings / Share | 12.08 |
| ROE | 75.3% |
| ROIC | 19.3% |
| Price / Revenue | 5.8 |
| Price / Book | 15.6 |
| Price / CF | 13.9 |
| Current Ratio | 1.7 |
| Cur.Liabilities / Tot.Liabilities | 0.2 |
| Financial Leverage | 3.50 |
| in Mils USD |
rolling-year up to March
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Revenue |
25,164
|
23,966
|
23,750
|
22,939
|
22,928
|
22,156
|
|
| Gross Profit |
19,028
|
19,152
|
19,538
|
18,922
|
18,788
|
17,944
|
|
| R&D |
4,222
|
4,189
|
3,856
|
3,553
|
3,737
|
4,048
|
|
| EBITDA |
12,716
|
12,744
|
12,607
|
12,974
|
12,765
|
11,602
|
|
| Operating Income |
8,913
|
9,557
|
10,009
|
10,108
|
9,983
|
8,850
|
|
| Net Income exc. Extra |
7,085
|
7,675
|
8,075
|
2,219
|
7,893
|
7,216
|
|
| per Share | |||||||
| Diluted avg Shares |
581
|
594
|
626
|
711
|
741
|
760
|
|
| EPS exc. Extra |
12.08
|
12.78
|
12.53
|
3.15
|
10.55
|
9.45
|
|
| Dividend |
6.56
|
5.95
|
5.41
|
4.77
|
4.15
|
3.37
|
|
| Div. Yield (an.) |
2.64%
|
2.93%
|
2.85%
|
2.80%
|
2.53%
|
2.25%
|
|
| Balance Sheet | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Total Assets |
62,539
|
61,669
|
63,997
|
71,164
|
77,862
|
75,116
|
|
| Cash, Eq & Invt ShortTerm |
10,566
|
8,012
|
26,301
|
32,172
|
38,398
|
34,740
|
|
| Total Current Assets |
21,299
|
18,813
|
35,151
|
40,689
|
46,456
|
42,206
|
|
| Total Non-Current Assets |
41,240
|
42,856
|
28,846
|
30,475
|
31,406
|
32,910
|
|
| Intangibles |
30,620
|
33,336
|
21,816
|
23,550
|
24,679
|
26,252
|
|
| Total Liabilities |
53,205
|
52,184
|
53,165
|
55,544
|
47,225
|
46,434
|
|
| Total Current Liabilities |
12,869
|
11,827
|
12,706
|
10,479
|
10,523
|
8,523
|
|
| Long Term Debt |
40,336
|
40,357
|
40,459
|
45,065
|
36,702
|
37,911
|
|
| Shareholder equity |
9,334
|
9,485
|
10,832
|
15,620
|
30,637
|
28,682
|
|
| Cash Flow | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Cash from Operations |
10,467
|
9,439
|
10,414
|
11,519
|
10,824
|
10,164
|
|
| Depreciation |
3,545
|
2,608
|
1,970
|
1,902
|
2,108
|
2,105
|
|
| Cash from Investing |
-5,490
|
1,924
|
2,988
|
11,039
|
-4,425
|
-8,985
|
|
| Capex |
632
|
644
|
699
|
651
|
750
|
358
|
|
| Cash from Financing |
-6,552
|
-11,034
|
-15,785
|
-16,175
|
-5,937
|
-1,147
|
|
| Stock Issued |
-3,396
|
-5,631
|
-10,129
|
-13,271
|
-2,875
|
-2,079
|
|
| Debt (LT) Issued |
751
|
-1,801
|
-2,121
|
676
|
204
|
3,974
|
|
| Free Cash Flow |
12,220
|
7,991
|
12,501
|
2,900
|
11,515
|
10,962
|
|
| Ratios | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Net Profit Margin |
28.2%
|
32.0%
|
34.0%
|
9.7%
|
34.4%
|
32.6%
|
|
| NCFO / Op.Income |
117.4%
|
98.8%
|
104.0%
|
114.0%
|
108.4%
|
114.8%
|
|
| Current Ratio |
1.7
|
1.6
|
2.8
|
3.9
|
4.4
|
5.0
|
|
| Financial Leverage D/E |
3.50
|
3.36
|
3.05
|
2.28
|
1.11
|
1.20
|
|
| Return on Capital Avg |
19.3%
|
20.6%
|
19.7%
|
3.8%
|
13.8%
|
12.6%
|
|
| Return on Shareholder Equity |
75.3%
|
75.6%
|
61.1%
|
9.6%
|
26.6%
|
26.2%
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available